These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The use and abuse of surrogate endpoints in clinical research in transfusion medicine. Arnold DM; Lim W Transfusion; 2008 Aug; 48(8):1547-9. PubMed ID: 18507746 [No Abstract] [Full Text] [Related]
4. Use and misuse of surrogate outcomes in arrhythmia trials. Connolly SJ Circulation; 2006 Feb; 113(6):764-6. PubMed ID: 16476858 [No Abstract] [Full Text] [Related]
5. [Clinical trials (III). The publication of the results]. Pascual J; de Pablo I; Gálvez MA; Hernández D Nefrologia; 2006; 26(1):25-30. PubMed ID: 16649423 [No Abstract] [Full Text] [Related]
6. Drug markers questioned. Ledford H Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695 [No Abstract] [Full Text] [Related]
7. Consensus on outcome measures for chronic pain trials. McQuay H Pain; 2005 Jan; 113(1-2):1-2. PubMed ID: 15621355 [No Abstract] [Full Text] [Related]
9. Are we ready to use surrogate end points and surrogate tissues to evaluate response to chemopreventive and therapeutic intervention? Lotan R Clin Cancer Res; 2000 Jun; 6(6):2126-8. PubMed ID: 10873060 [No Abstract] [Full Text] [Related]
10. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Choy EH; Mease PJ Rheum Dis Clin North Am; 2009 May; 35(2):329-37. PubMed ID: 19647146 [TBL] [Abstract][Full Text] [Related]
11. An inexplicable oversight and a misconception in research. Ingenbleek Y; Cynober L J Nutr Health Aging; 2005; 9(3):199. PubMed ID: 15864401 [No Abstract] [Full Text] [Related]
12. Surrogate and mediating endpoints: current status and future directions. Prentice RL J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455 [No Abstract] [Full Text] [Related]
14. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease. Colatsky TJ Curr Opin Investig Drugs; 2009 Mar; 10(3):239-44. PubMed ID: 19333881 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers in Alzheimer's disease: not yet surrogate endpoints. Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266 [TBL] [Abstract][Full Text] [Related]
16. Surrogate markers in clinical studies: problems solved or created? Manns B; Owen WF; Winkelmayer WC; Devereaux PJ; Tonelli M Am J Kidney Dis; 2006 Jul; 48(1):159-66. PubMed ID: 16797400 [No Abstract] [Full Text] [Related]